Destiny Pharma set for next phase

There was a sharp rise in the share price of Destiny Pharma (LON: DEST) following the results of the phase 2b clinical study on the use of XF-73 nasal gel for the prevention of post-surgical infections. The shares have fallen back, and they remain attractive considering the potential for this antimicrobial treatment.

The study covered 124 patients. Destiny says there was a 99.5% reduction of infection in the nose 24 hours before open heart surgery. XF-73 is also safe and well tolerated. Ther...

You are unauthorized to view this page.

Previous articleBushveld to receive $30m to increase capacity at Enerox
Next articleNew AIM admission: ActiveOps
Avatar photo
Andrew Hore is the publisher of AIM Journal, which is an online monthly publication covering the Alternative Investment Market.